STRATA Skin Sciences, Inc.

STRATA Skin Sciences, Inc. is a U.S.-based medical technology company focused on dermatology devices and treatment systems. Its portfolio includes excimer laser and lamp platforms used by dermatologists to treat psoriasis, vitiligo, acne, and other skin conditions, with sales and procedures centered in the United States and select international markets.

−1,9 %

58,3 %

−20,4 %

−8,5 %

0.58

0.48

— STRATA Skin Sciences, Inc.
%
Dermatology recurring procedures72% Treatment revenue from XTRAC procedures and TheraClear device placements recognized over usage.
Dermatology procedures equipment28% Sales of excimer lasers, lamp systems, accessories, and related equipment to practices.

The company sells primarily to dermatology practices and physicians that treat chronic and recurring skin conditions...

  • Dermatology practicesprimary

    Buy XTRAC, Pharos, and VTRAC systems to treat psoriasis, vitiligo, and other skin diseases in-office.

  • Recurring procedure officesprimary

    Place STRATA devices and generate treatment revenue as patients return for repeated sessions.

  • Acne treatment providerssecondary

    Use TheraClear X for acne-related skin conditions and related patient care workflows.

  • International dermatology customerssecondary

    Purchase equipment and procedures outside the U.S. where the company has international exposure.

STRATA is headquartered in the United States and its reported recurring procedures activity is concentrated there...

  • •United States is the core market for devices and recurring procedures
  • •International customer sales can take longer to collect
  • •Imported components expose the business to tariff and trade policy risk
  • •U.S. reimbursement coverage supports adoption of XTRAC procedures

STRATA’s strategy centers on expanding installed base usage, placing devices in dermatology offices, and converting...

01
Expand recurring procedure utilizationshort-term

Recurring treatments create repeat revenue tied to installed devices and patient flow.

02
Increase installed base and device placementsmedium-term

A larger installed base supports future procedure volume and customer retention.

03
Optimize device lifecycle economicsmedium-term

Refurbishing and redeploying units can lower capital needs versus building new systems.

The business is exposed to reimbursement, adoption, and utilization risk because a meaningful share of revenue depends...

high

Tariffs and trade restrictions

Imported products or components may become more expensive and less competitive.

Scope
Product costs, pricing, and demand
Materiality
high
high

Reimbursement and utilization dependence

Recurring procedure revenue depends on insurance coverage and patient treatment volume.

Scope
XTRAC and related dermatology procedures
Materiality
high
high

Goodwill and intangible impairment

Device and reporting-unit values depend on future cash flow assumptions.

Scope
Dermatology recurring procedures reporting unit
Materiality
high
medium

International collection timing

The company noted longer payment cycles from international customers.

Scope
Accounts receivable and cash conversion
Materiality
medium
Revenue recognition for recurring procedures
Can shift revenue between periods
Deferred revenue on domestic placements
Affects reported revenue and contract liabilities
Goodwill impairment
Can create non-cash charges if expected cash flows weaken
Sales tax liability estimates
Can alter liabilities, operating expense, and goodwill carrying value

Strata Critical Medical, Inc.

SRTA · Services-Health Services

Sensus Healthcare, Inc.

SRTS · Surgical & Medical Instruments & Apparatus

Dermata Therapeutics, Inc.

DRMA · Pharmaceutical Preparations

Caring Brands, Inc.

CABR · Perfumes, Cosmetics & Other Toilet Preparations

SKINVISIBLE, INC.

SKVI · Pharmaceutical Preparations

ENDRA Life Sciences Inc.

NDRA · Electromedical & Electrotherapeutic Apparatus

: 29.4.2026